- Report
- March 2024
- 196 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Report
- February 2024
- 200 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- May 2024
- 93 Pages
Global
From €5379EUR$5,600USD£4,631GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4754EUR$4,950USD£4,093GBP
- Report
- September 2022
- 247 Pages
Global
From €5042EUR$5,250USD£4,341GBP
- Report
- August 2018
- 86 Pages
Global
From €5715EUR$5,950USD£4,920GBP
- Report
- April 2023
- 112 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- January 2022
- 200 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- January 2022
- 200 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- May 2022
- 171 Pages
Global
From €2401EUR$2,500USD£2,067GBP
Urothelial Cell Carcinoma (UCC) is a type of cancer that affects the cells that line the urinary tract. Oncology drugs are used to treat UCC, and the UCC drug market is a subset of the larger oncology drug market. UCC drugs are typically divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific molecules or pathways that are involved in the growth and spread of cancer cells. Immunotherapies are designed to stimulate the body's own immune system to fight cancer cells.
The UCC drug market is highly competitive, with many companies developing and marketing drugs for the treatment of UCC. Some of the major players in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. These companies are actively researching and developing new drugs to treat UCC, as well as marketing existing drugs to treat the disease. Show Less Read more
